Boston Scientific (BSX) AI Stock Analysis

Company Guidance

For fourth quarter 26, Boston Scientific guided to organic revenue declines of -1% to -3%, reported revenue decline in a range of down 3% to down 1%, operational and organic revenue decline in a range of down 3% to down 1%, and adjusted EPS of $0.77 to $0.79, including a cyber headwind of approximately 200 to 300 basis points and roughly $0.04 to $0.05 of EPS impact; for full-year 2026, it expects organic revenue growth of 4%, reported revenue growth of approximately 4.25%, operational and organic growth of approximately 3.75%, adjusted operating margin of approximately 27.6%, adjusted below-the-line expense of approximately $485 million, adjusted tax rate of approximately 12%, free cash flow of approximately $3.6 billion, and adjusted EPS of $3.16 to $3.18, representing growth of 3% to 4% year-over-year versus 2025 including an approximate $0.06 headwind from foreign exchange; for 2027, excluding Penumbra, it expects to be challenged to grow revenue and adjusted EPS, with the underlying base business consistently growing about 6% year-over-year, about a point of impact due to comp pricing issues, WATCHMAN market dynamics of about -7% to -8%, and additional pressure from a competitive launch, while it expects restructuring savings of over $500 million over the next 3 years and over half of those savings exiting 2027; it expects growth to improve in 2028 and above market WAMGR in 2029, with WAMGR at about 7% and maybe 7% to 8% over the next 3 years.